HT
RARE icon

Headlands Technologies’s Ultragenyx Pharmaceutical RARE Stock Holding History

Headlands Technologies’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$845K Sell
25,305
-25,495
-50% -$633K 0.09% 286
2026
Q1 		$1.06M Buy
50,800
+22,593
+80% +$509K 0.12% 194
2025
Q4 		$649K Buy
28,207
+2,778
+11% +$91.4K 0.05% 351
2025
Q3 		$765K Buy
25,429
+13,446
+112% +$403K 0.06% 283
2025
Q2 		$436K Buy
11,983
+10,360
+638% +$373K 0.05% 335
2025
Q1 		$58.8K Buy
+1,623
New +$67.5K 0.01% 679
2024
Q4 		– Sell
-12,052
Closed -$669K – 1511
2024
Q3 		$669K Buy
12,052
+5,928
+97% +$302K 0.08% 282
2024
Q2 		$252K Buy
6,124
+5,530
+931% +$236K 0.03% 418
2024
Q1 		$27.7K Buy
+594
New +$28K 0.01% 843
2023
Q4 		– Sell
-3,351
Closed -$119K – 1236
2023
Q3 		$119K Buy
3,351
+1,127
+51% +$44.7K 0.06% 269
2023
Q2 		$103K Buy
2,224
+2,186
+5,753% +$101K 0.03% 382
2023
Q1 		$1.52K Buy
+38
New +$1.63K ﹤0.01% 441

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Headlands Technologies's RARE Position: Q2 2026 in Review

Headlands Technologies reduced its Ultragenyx Pharmaceutical (RARE) stake by 50% in Q2 2026, selling an estimated $633K and leaving 25,305 shares worth $845K. The position accounts for 0.09% of the portfolio, ranked #286.

Headlands Technologies first reported a position in RARE in Q1 2023 and has held it in 12 quarters since. The position peaked at $1.06M in Q1 2026. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Headlands Technologies held 25,305 shares of Ultragenyx Pharmaceutical worth $845K as of Q2 2026.
  • Headlands Technologies sold 25,495 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $633K.
  • Ultragenyx Pharmaceutical made up 0.09% of Headlands Technologies's portfolio in Q2 2026, its #286 holding.
  • Headlands Technologies first reported a position in Ultragenyx Pharmaceutical in Q1 2023 and has held it in 12 quarters since.
  • Headlands Technologies's Ultragenyx Pharmaceutical position peaked at $1.06M in Q1 2026.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.